No profile data available.
Neurogene Inc. (NGNE) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 131 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$90.35 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $528.30 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
Neurogene reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$528.30 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Design Therapeutics, Inc. (DSGN), Bright Minds Biosciences Inc. (DRUG), Regenxbio Inc. (RGNX), Ovid Therapeutics Inc. (OVID).